COMPANY

Walden Biosciences

HQ: Cambridge, MA source · waldenbiosciences.com ↗ · New England

Keywords: renal kidney diseases monoclonal antibody small molecule Diabetic Nephropathies Primary Focal Segmental Glomerulosclerosis Minimal Change Disease Primary Immunoglobulin A Nephropathy Primary Membranous Nephropathy WAL0921

Location: Cambridge, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

2Trials (company is sponsor)

Timeline

Jul 2, 2024 Trial start Phase 2: Study of WAL0921 in Patients With Glomerular Kidney Diseases source ↗
May 31, 2023 Trial start Phase 1: Single Ascending Dose Study of WAL0921 in Healthy Subjects source ↗

Upcoming milestones

2027-03 (ESTIMATED) · Phase 2 · Study of WAL0921 in Patients With Glomerular Kidney Diseases · NCT06466135

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT06466135	Study of WAL0921 in Patients With Glomerular Kidney Diseases	Phase 2	Recruiting	Jul 2, 2024	2027-03 (estimated)
NCT05891366	Single Ascending Dose Study of WAL0921 in Healthy Subjects	Phase 1	Completed	May 31, 2023	Jan 9, 2024 (actual)